<DOC>
	<DOC>NCT01580306</DOC>
	<brief_summary>The main objective of this study is to investigate the influence of mild, moderate and severe renal impairment on the pharmacokinetics and safety of BI 201335 in comparison to a control group with normal renal function after single dose of BI 201335.</brief_summary>
	<brief_title>Pharmacokinetics and Safety of BI 201335 in Patients With Mild to Severe Renal Impairment</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis C</mesh_term>
	<mesh_term>Renal Insufficiency</mesh_term>
	<criteria>Inclusion criteria: Male and female healthy subjects with normal renal function and subjects with impaired renal function in relatively good health Exclusion criteria: Any relevant deviation from healthy conditions for healthy volunteers or significant diseases other than renal impairment for the renal impaired subjects</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2015</verification_date>
</DOC>